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ABSTRACT 
Antagonism of 5HT6 receptors is associated with pro-cognitive effects in 
preclinical species, suggesting a therapeutic potential for this mechanism in 
Alzheimer’s disease (AD) and other cognitive diseases.  In a phase 2 dose 
study, SB742457, a novel 5HT6 antagonist, showed increasing pro-
cognitive effects in patients with AD as the dose increased, with a pro-
cognitive signal in AD patients at a dose of 35mg/day superior to the other 
doses tested (5 and 15mg/day).  In this paper, we describe the quantification 
and pharmacological selectivity of a new 5HT6 PET ligand (
11
C-
GSK215083) in healthy volunteers, and its use to measure occupancies 
achieved at various doses of SB742457.  
Results: Kinetic analysis of 
11
C-GSK215083 uptake in human brain 
demonstrated the MA2 model to represent the method of choice when a 
blood input was available and the full tissue reference method when no 
input was available.  Pharmacological dissection of the in vivo 
11
C-
GSK215083 specific binding showed the ligand bound mostly the 5HT6 in 
the striatum (blocked by SB742457, but not by the selective 5HT2A 
antagonist ketanserin) and to 5HT2A in the frontal cortex (blocked by both 
ketanserin and SB742457).  Repeated administration of SB742457 (3, 15 
and 35mg/day) saturated the 5HT6 receptors at all doses.  In cortex, 5HT2A 
receptors occupancy was 23% (3mg/day), 35% (15mg/day) and 57% 
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(35mg/day), suggesting a progressive engagement of 5HT2A as the dose 
increased. 
Conclusion: Collectively, these data support the use of 
11
C-GSK215083 as a 
5HT6 clinical imaging tool, and suggest that blocking both the 5HT6 and 
5HT2A receptors may be required for the optimal therapeutic action of 
SB742457 in AD. 
 
Keywords 
5HT6; human kinetic modelling; 
11
C-GSK215083; SB742457; Alzheimer’s 
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INTRODUCTION 
The 5HT6 receptor is a seven transmembrane receptor expressed in the 
mammalian central nervous system, through which serotonin acts to 
regulate a number of biological processes (1).  Both in vitro and in vivo 
imaging studies have demonstrated high levels of this receptor in the basal 
ganglia and limbic structures of the brain, moderate levels in the cortical 
structures and low levels in the cerebellar regions (2,3).   Preclinical studies 
have demonstrated cognitive-enhancing effects of 5HT6 antagonism (4), 
prompting the development of 5HT6 antagonists for the symptomatic 
treatment of cognitive disorders such as Alzheimer disease (AD).  
SB742457 is a novel 5HT6 receptor antagonist under development for 
cognitive remediation in AD (5,6,7).  In a phase 2 dose ranging study (5), 
three doses levels were investigated (5, 15, and 35mg once daily for 24 
weeks) in a randomized, double-blind, placebo-controlled study in 357 
subjects with mild-to-moderate probable AD.  The highest dose-level 
separated from placebo on the Clinician's Interview-Based Impression of 
Change with caregiver input (CIBIC+) score, while the lower doses did not.  
These data suggest the usefulness of 5HT6 antagonism in the symptomatic 
treatment of AD. 
Occupancies of the 5HT6 receptor achieved in these clinical studies have 
not yet been conveyed.  We previously reported the development, 
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radiosynthesis, preclinical assessment and initial human evaluation of the 
selective, high affinity 5HT6 receptor PET ligand, 
11
C-GSK215083 (3,8).  
Collectively, these data suggest 
11
C-GSK215083 would be a useful tracer to 
label 5HT6 receptors in human brain.   
In this study, we report firstly the kinetic methods to derive 
11
C-GSK215083 
binding potential (BP) in the human brain.  Secondly, investigation of 
11
C-
GSK215083 selectivity for both the 5HT6 and 5HT2A receptors (as this 
radioligand displayed only ~5-fold difference in selectivity for the 5HT6 
versus 5HT2A (3)); and thirdly, evaluation of 5HT6 and 5HT2A receptor 
occupancy achieved upon repeated administration of various doses of 
SB742457.  
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MATERIALS AND METHODS 
Radiosynthesis of [
11
C]-GSK215083 
GSK215083 and the N-desmethyl precursor were prepared according to 
published procedures (9,10).  All other chemicals and solvents were of 
analytical grade. 
PET studies were performed at two facilities: the Centre for Addiction and 
Mental Health (CAMH) in Toronto, Canada and the Rossendorf PET Centre 
in Dresden, Germany.  Both studies were approved by a local research 
ethics board and were conducted in accordance with Good Clinical Practice 
guidelines, all applicable regulatory requirements and the Code of Ethics of 
the World Medical Association (Declaration of Helsinki).  All subjects 
provided written informed consent.  Both studies were completed prior to 
2008 and are therefore not included in trial registries.  
The radiolabelling methods for radiosyntheses at Dresden are given in the 
Supplementary Information, and for Toronto have been previously 
described (8).   
 
Toronto Study 
For this study scans were obtained with an arterial input function in order to 
perform model-based kinetic analysis of 
11
C-GSK215083 brain uptake.  
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Seventeen healthy subjects (33±8 years; 69±15Kg (mean±SD); 8 males and 
9 females) were enrolled in this single session study to assess brain 
biodistribution of 
11
C-GSK215083.  Medical history, physical examination, 
electrocardiogram and vital sign information were collected at screening and 
at follow-up (within 7 days of the scan).   
On the study day, subjects were cannulated in the antecubital vein for tracer 
administration and in the contralateral radial artery for blood sampling. 
Subjects received a bolus intravenous injection of 
11
C-GSK215083 
(357±15.34MBq, 3.25±1.40µg). Following injection, dynamic data were 
acquired in list-mode using a Biograph HiRez XVI PET camera system 
(Siemens Molecular Imaging; (11)).  A low-dose CT transmission scan was 
obtained for attenuation correction.   
For all scans, list-mode data were converted into a sequence of 26 frames 
(8x15 seconds, 3x1 minute, 5x2 minutes, 5x5 minutes, 5x10 minutes) for a 
total of 90 minutes.  For each 3-dimensional sinogram, data were 
normalised and attenuation and scatter-corrected before Fourier rebinning 
and conversion into 2-dimensional sinograms.  Image reconstruction was 
conducted using a 2-dimensional filtered back-projection algorithm, with a 
ramp filter at the Nyquist cut-off frequency.  A Gaussian filter of 5mm in 
full width half maximum was applied and images calibrated to Bq/cm
3
.  
Images were combined to create a single dynamic dataset on which regions 
of interest (ROI) were described and time-activity curves (TACs) derived. 
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During acquisition, arterial blood samples were collected for the 
determination of whole-blood and plasma input functions. The fraction of 
radioactivity in the plasma corresponding to authentic radioligand was 
determined by radio-HPLC from nine discrete arterial blood samples 
(between 2.5 and 75 minutes).  The metabolite analysis method is described 
in Supplementary Information. 
 
Dresden Study 
This study was performed for pharmacological characterisation of 
11
C-
GSK215083 brain uptake, along with characterisation of the receptor 
occupancy achieved upon repeat-dosing with SB742457.  Eighteen healthy 
male subjects (57±4 years; 81±10Kg) were recruited into this open-label, 
adaptive study (AZ3103943).  Three groups were enrolled: 
Group 1 (n=4) assessed the test-retest reliability for each subject of two 
independent administrations of 
11
C-GSK215083, 4-7 days apart (Figure 
1A).  
Group 2 (n=6) was used for pharmacological characterisation of the regional 
binding of 
11
C-GSK215083.  In addition to its affinity for 5HT6 receptors, 
the PET ligand, 
11
C-GSK215083, also possesses ~5-fold lower affinity for 
the 5HT2A receptor (3).   Therefore, we used ketanserin, a selective 5HT2A 
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antagonist, to test for the existence of detectable binding to 5HT2A 
receptors, and SB742457 to detect binding to 5HT6 receptors.  Four subjects 
received a baseline 
11
C-GSK215083 scan followed by two further PET 
scans, after SB742457 (175mg, p.o. 5 hours prior to 
11
C-GSK215083 
administration) and after ketanserin (0.1mg/kg, by slow intravenous 
injection, 2 hours prior to 
11
C-GSK215083 administration) respectively, in a 
randomised fashion, 7 days apart.  The remaining two subjects received a 
baseline scan, a second scan following SB742457 (175mg) and a third scan, 
7 days later (Figure 1B). 
Group 3 (n=8) characterised the time- and dose-occupancy relationship of 
SB742457 in brain.  Each subject underwent three PET scans.  Scan 1 was a 
baseline scan with scans 2 and 3 following repeated once daily dosing of 
SB742457 on two occasions between 7 and 28 days of dosing.  Four 
subjects received a loading dose of SB742457 (175mg) on day 1 followed 
by 35mg daily for 21 or 28 days (2 subjects per group).  Subjects were 
randomised to receive two scans on days 7, 14, 21, and 28, such that two 
independent data points were collected for each time-point (Figure 1C).  
Similarly, two further subjects received SB742457 (70mg) followed by 
15mg daily for 14 days, and the last two subjects received 15mg followed 
by 3mg daily for 14 days.  All four subjects were scanned on days 7 and 14 
(Figure 1D).  Scans were conducted approximately 5 hours after SB742457 
dosing. 
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Safety assessments included medical history, physical examination, adverse 
event reporting, clinical laboratory assessments and ECG, blood pressure 
and pulse rate measurements (Supplementary Information).  Blood samples 
were collected for PK analysis of SB742457 in plasma from subjects in 
Groups 2 and 3 prior to, and on completion of each scan where SB742457 
was administered (Supplementary Information). 
For each subject, a low-dose CT transmission scan was obtained for 
attenuation correction.  Dynamic data were acquired in list-mode using an 
ECAT EXACT HR
+
 PET camera system (Siemens Molecular Imaging).  
Recording of emission data began on bolus intravenous injection of 
11
C-
GSK215083 (338±37MBq, 6.04±1.61µg).  For all scans, list-mode data 
were converted into a sequence of 26 frames (8x15 seconds, 3x1 minute, 
5x2 minutes, 5x5 minutes, 5x10 minutes), for a total of 90 minutes.  
Normalisation and data reconstruction was conducted as in the Toronto 
study.  Images were combined to create a single dynamic dataset on which 
ROI were described and TACs derived.    
 
MRI Scans 
In both studies, a T1-weighted anatomical 3D MRI scan was obtained for 
each subject (1.5-T Signa-Excite HD; GE Healthcare) for co-registration 
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with the PET data and identification of discrete regional volumes 
(resolution, 1x1x1mm).   
 
Data Processing and Kinetic Analysis 
Dynamic PET data were corrected for motion via frame-to-frame image 
registration and aligned with the structural T1-MRI scan using SPM5 
(Wellcome Trust Centre for Neuroimaging) with a normalised mutual-
information cost function. 
ROI (Caudate, Putamen, Cortical regions, Hippocampus and Cerebellum) 
were defined on the MRI image for each subject using a region template 
(12).  MRI images were co-registered to the corresponding summed PET 
image, and ROI applied to the dynamic PET images to generate tissue 
TACs.  Of the cortical regions (Frontal, Parietal, Occipital, Temporal) 
analytical results were very similar within each subject and subsequently 
only those for the Frontal Cortex are presented.  
Toronto Data Analysis:  Data from the 17 subjects were fitted initially to 4 
separate arterial plasma input models: 3 compartmental models and the 
multi-linear model, MA2 (13), each containing a parameter to account for 
dispersion of blood in the withdrawal cannula (14):  
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Models fitted included: A one-tissue compartment model with clearance and 
rate constants, K1 and k2, between plasma and tissue (2k); a two-tissue 
compartment model, with one-reversible tissue compartment feeding a 
second-irreversible tissue compartment with rate constant k3 (3k); a two-
reversible tissue compartment model with exchange rate constants k3 and k4 
(4k); and the multi-linear model, MA2, applicable to reversible radioligands 
(13), and involves linear transforms of the plasma and tissue data based on a 
reversible 4k model.  Fits of the data to these models were compared on the 
basis of an Akaike information criterion (15), with individual data points 
weighted by frame-length.  In addition, data were also analysed using a 
simplified reference tissue model (SRTM) and full reference tissue model 
(FRTM) using the cerebellum as the reference region (16).    
Dresden Data Analysis:  Metabolite corrected arterial plasma input 
functions were not available, and hence data were analysed using the SRTM 
and FRTM models. 
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RESULTS 
Kinetic Modelling of the 5HT6 PET Radioligand, 
11
C-GSK215083 
A representative baseline image for 
11
C-GSK215083 uptake is given in 
Figure 2, where 
11
C-GSK215083 readily enters the brain with highest 
uptake observed in the caudate and putamen (striatum), moderate levels in 
the cortex and lowest uptake in the cerebellum. 
Data from the Toronto subjects were analysed using the three 
compartmental models defined above along with the multi-linear model, 
MA2.  Model 2k was the least favourable of these three models in all 
regions for all subjects.  For 10 subjects, the 4k model performed better than 
the 3k model.  However the relatively ‘slow’ kinetics of this radioligand was 
associated with model 3k performing better in all or most regions of the 
remaining 7 subjects. 
For 3 of the 7 subjects that best fitted the 3k model, large estimates of VT 
were obtained in some/all regions when the 4k model was applied to these 
datasets.  However, there was no consistent distribution of “best-fit models” 
between the high binding striatal regions and other regions with relatively 
lower levels of binding.  When the MA2 model was applied to the ROI data 
there were no apparent outliers in the estimates of VT across all regions for 
the 17 subjects, as determined via visual inspection.  Estimates of the 
regional VT are given in Table 1, for both the 4k and MA2 models 
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(excluding outliers for model 4k), where estimates from the 4k model were 
consistently higher than the MA2 model.  
Regional values for BPND were subsequently calculated from the estimates 
of VT obtained from the 4k and MA2 models, assuming the cerebellum was 
a suitable reference region (Table 2).  In addition, BPND was also estimated 
from the regional TAC using the FRTM and the SRTM with the cerebellum 
acting as the reference region.  These models were applied to all 17 subjects, 
and the results given in Table 2.  Of the two reference region models, 
FRTM showed less inter-subject variability in the high binding striatal 
regions compared to the SRTM.  Whilst there was a close agreement in the 
estimates between the two reference tissue models and model MA2 in 
regions with low and intermediate binding regions (e.g. hippocampus and 
cortex), there was more variation observed between models in the high 
binding striatal regions.   
Correlations between the estimates of BPND obtained from the four models 
across the striatal, hippocampal and cortical regions are given in Figure 3. 
Collectively, these data suggest the MA2 model can be used as a preferred 
method for analysing human 
11
C-GSK215083 PET data when a blood input 
is available, and the FRTM method as a suitable alternative in the absence 
of any arterial input function. 
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11
C-GSK215083 Test-Retest 
Test-retest data from the four Dresden subjects scanned at Dresden are 
given in the Supplementary Information. 
 
11
C-GSK215083 Pharmacological Characterisation  
The effect of the 5HT2A antagonist, ketanserin, and the dual 5HT6/5HT2A 
antagonist, SB742457, on 
11
C-GSK215083 BPND in the brain at 5 hours 
post-administration are given in Table 3.  The caudate and putamen both 
represent 5HT6-densely populated structures whereas the frontal cortex 
represents a 5HTA-rich region.  SB742457 occupied 64 and 84% of the 
putamen and caudate signal, respectively, and 63% of the frontal cortical 
signal.   
Ketanserin occupied 25% of the frontal cortical signal at 5 hours post-
administration, whilst occupying only 3 and 16% of the putamen and 
caudate signal, respectively.  Interestingly, very high occupancies in both 
the putamen and caudate were observed (ranging from 70-86%) following 
ketanserin administration in the two subjects (6 and 7) who received 
SB742457 followed by ketanserin 7 days later.  In order to determine 
whether these high occupancies were due to ketanserin itself or a potential 
“carry-over” of SB742457 from the previous scan 7 days earlier, two further 
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subjects were studied who received SB742457 and were scanned 5 hours 
and 7 days post-administration (subjects 9 and 10; Table 3).  Data from 
these two subjects demonstrated occupancies of 57% (5 hours) and 56% (7 
days) in the putamen and 91% (5 hours) and 87% (7 days) in the caudate.  
These findings strongly suggest the ketanserin data for subjects 6 and 7 
would have been compromised from SB742457 being administered 7 days 
earlier, and that SB742457 is present in the CNS for longer than 7 days. 
 
11
C-GSK215083 Dose-Occupancy  
The effect of repeated SB742457 administration on 
11
C-GSK215083 uptake 
into the human brain was assessed at three dose-levels, given in Table 4 and 
Figure 4.  Repeated exposure of 3, 15 and 35mg/day exhibited near- to 
complete-occupancy of the 5HT6 containing regions, (putamen and caudate) 
and a dose-dependent increase in occupancy in the frontal cortex. 
 
Correlation of Plasma Pharmacokinetic and PET Pharmacokinetic 
Data 
Plasma pharmacokinetic (PK) data following acute administration of 
SB742457 (175mg) in humans is given in Figure 5A.  These PK data 
demonstrate the mean concentration of SB742457 to be ~30ng/ml 96 hours 
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post-administration.  A subsequent correlation of plasma-PK data together 
with the PET-PK data for the frontal cortex region following repeated 
dosing of SB742457 (Figure 5B) showed a clear dose-occupancy curve 
exhibiting an ED50 of 92.38ng/ml of SB742457 in the plasma. 
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DISCUSSION 
This paper reports (1) kinetic modelling of the 5HT6 PET radioligand, 
11
C-
GSK215083, in human brain using both plasma input and reference tissue 
quantification approaches; (2) pharmacological characterisation of 
11
C-
GSK215083 in brain utilising the pharmacological tools, ketanserin 
(5HT2A-selective) and SB742457 (5HT6/5HT2A-selective); and (3) 5HT6 
and 5HT2A occupancies achieved upon repeat-dosing with SB742457. 
Of the kinetic models that required the use of an arterial input function, the 
MA2 model represented the method of choice for analysing human 
11
C-
GSK215083 PET data, with all data-sets able to fit to this model (Tables 1 
and 2), consistent with the notion that 
11
C-GSK215083 represents a 
reversible radioligand with slow kinetics in high binding regions.  Of the 
reference tissue models, the FRTM demonstrated slightly lower inter-
subject variability compared to the SRTM (Table 2).  Collectively, these 
data indicate the MA2 model could be used for the analysis of human 
11
C-
GSK215083 PET data when a blood input is available, and in the absence of 
a blood input the FRTM represents a suitable alternative. 
In addition to its affinity for 5HT6 receptors, the PET ligand, GSK215083, 
also possesses ~5-fold lower affinity for the 5HT2A receptor (3).  5HT2A 
receptors are known to exist in high densities in the cortex with moderate-
to-negligible levels in striatum, and low levels in cerebellum (17).  
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Subsequently co-localisation of 5HT6 and 5HT2A receptors in particular 
areas of the brain require the use of selective compounds in order to 
delineate the uptake of 
11
C-GSK215083 associated with each of these target 
proteins.  
Following acute dosing with the 5HT2A receptor antagonist, ketanserin, 
occupancies of ~25% in the frontal cortical region and 3-16% in the striatal 
regions were observed.  In addition, acute administration of the dual 
5HT6/5HT2A antagonist, SB742457, demonstrated occupancies of ~63% in 
the frontal cortex and 64-84% in the striatal regions (Table 3).   
The apparent lack of occupancy in the striatal regions following ketanserin 
and the high occupancy following SB742457 administration, suggests this 
brain region to be mainly 5HT6-containing.  In contrast, the cortex is known 
to contain a much higher density of 5HT2A receptors compared to 5HT6 
receptors.  The high level of occupancy in the cortical region by SB742457 
almost certainly points towards blockade of the 5HT2A receptor, thereby 
reflecting the dual action of this compound on both 5HT6 (striatal region) 
and 5HT2A receptors (frontal cortex).   
The unexpected discovery of a single dose of SB742457 (175mg) producing 
prolonged occupancy at the striatal 5HT6 receptors for a period of at least 7 
days was revealed following randomisation of dosing for ketanserin and 
SB742457 in the same subjects.  Human plasma-PK data for this compound 
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demonstrated a mean concentration of SB742457 (175mg) to be ~30ng/ml 
at four days post-administration, and hence negligible levels were expected 
to be present at 7 days post-administration (Figure 5A).  Consequently, for 
SB742457 the plasma-PK data was not reflected by the tissue-occupancy 
data measured at 7 days post-administration, and this is most probably due 
to the sub-nanomolar affinity of this compound for the 5HT6 receptor in the 
striatal tissue (0.25nM;(6)). 
Repeated dosing of SB742457 in healthy subjects demonstrated a dose-
dependent increase in occupancy of the 5HT2A receptors in the frontal 
cortex whilst maintaining a near-to complete-occupancy in the striatal 
regions at all dose-levels administered (Table 4, Figure 4).  The ~40-fold 
lower affinity of SB742457 for the 5HT2A (Ki=10nM;(6)) compared to the 
5HT6 receptor (Ki=0.25nM) may account for this dose-occupancy effect 
observed for the 5HT2A receptors in the cortex.   
Chronic dosing of SB742457 to subjects with mild-to-moderate AD has 
previously demonstrated a statistically significant improvement in the 
CIBIC+ scale over a 24-week period (5).  In this study, three doses levels 
were investigated (5, 15, and 35mg once daily for 24 weeks) in a 
randomized, double-blind, placebo-controlled study in 357 subjects with 
mild-to-moderate probable AD.  The highest dose-level (35mg) separated 
from placebo on the CIBIC+ score, while the lower doses did not.  The 
current PET study indicates that the pharmacological differences between 
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the three doses were not related to various degree of occupancy of 5HT6 
receptors (which appeared to be saturated at these three dose regimens), 
rather, the difference between low and high doses was the progressive 
involvement of 5HT2A receptors.  These data suggest that antagonism at 
both receptors is required for therapeutic effects of SB742457.   
Antagonism of the human 5HT2A and D2 receptors in patients suffering 
with schizophrenia via the commonly used anti-psychotic, risperidone, has 
previously demonstrated positive effects on working memory, executive 
functioning and attention, whereas improvement in verbal learning and 
memory have been more inconsistent (18).  In a recent study by Rainer (19) 
34 patients with a DSM-IV diagnosis of dementia (Alzheimer’s type, 
vascular, mixed or with Lewy bodies) were treated with flexible doses of 
risperidone (0.5-2mg/day) for 8 weeks and at the end of treatment, 
improvements in symptoms (Clinical Global Impression of Change scale) 
were reported for 82% of patients, and additionally, cognitive function was 
maintained throughout the treatment period. 
Studies reported in the literature indicate SB742457 enhances cognitive 
performance in patients with mild-to-moderate AD (5,6), which is purported 
to be via antagonism of the 5HT6 receptor.  Since SB742457 also 
demonstrates a high affinity for the 5HT2A receptor (albeit ~40-fold lower 
than the 5HT6) it must be considered whether antagonism of this receptor 
may also play a role in enhancing the cognitive-enhancing properties of 
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SB742457.  Current clinical literature does not support cognitive-enhancing 
effects of SB742457 via antagonism of the 5HT2A receptor alone, however, 
the effect of antagonising both the 5HT6 and 5HT2A simultaneously should 
be considered as a possible mechanism of action for SB742457. 
In order to fully elucidate the mechanism of action for the cognitive-
enhancing properties of SB742457, further studies will be required which 
combine both imaging methods and efficacy assessments of cognitive 
performance (for example, ADAS-Cog and CIBIC+) in order to correlate 
clinical benefit with receptor occupancy for potential therapeutic benefit of 
this compound in AD. 
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CONCLUSION 
This paper reports full kinetic modelling of the 5HT6 PET radioligand, 
11
C-
GSK215083, in human brain, where the MA2 model represents the method 
of choice for analysing 
11
C-GSK215083 PET data when a blood input is 
available, and the FRTM when a blood input is not available.  
Pharmacological evaluation suggests that 
11
C-GSK215083 binds to the 
5HT6 in the striatum, and to the 5HT2A in the cortex.  Furthermore, the 
data suggest that for SB742457 a regimen of 35mg/day would be associated 
with antagonism at both receptors, whilst lower doses of 5 and 15mg/day 
would block only the 5HT6 receptors.  These data suggest that engagement 
of both 5HT2A and 5HT6 receptors might be desirable to achieve superior 
efficacy of SB742457 in AD. 
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FIGURE LEGENDS 
FIGURE 1. Study design. Subjects were divided into three groups.  (A) 
Test-retest (n=4); (B) Pharmacological characterisation of 
11
C-GSK215083 
for the 5HT6 receptor in the striata utilising SB742457, and 5HT2A 
receptor in the cortex utilising ketanserin (n=6); (C) and (D) Time- and 
dose-occupancy of SB742457 (n=8) where scan 1=baseline scan and scans 2 
and 3 following repeated once daily dosing of SB742457 at two time 
intervals between 7 and 28 days of dosing. 
 
FIGURE 2. Baseline PET image demonstrating heterogeneous 
biodistribution of 
11
C-GSK215083 (scale bar=%ID/L). 
 
FIGURE 3. Correlations between the estimates of BPND obtained from the 
four kinetic models across the striatal, hippocampal and cortical regions. (A) 
4k vs MA2; (B) FRTM vs SRTM; (C) SRTM vs MA2; and (D) FRTM vs 
MA2. 
 
FIGURE 4. Graph demonstrating dose-dependent increase in occupancy of 
the 5HT2A receptor following increasing doses of SB742457 in the frontal 
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cortex, and near-to-complete occupancy of the 5HT6 receptor at all doses 
administered (FRTM analysis). 
 
FIGURE 5. Pharmacokinetic data for SB742457.  (A) Human plasma-PK 
data for SB742457; (B) Correlation of plasma-PK data vs percent 5HT2A 
PET receptor occupancy (FRTM) at different doses of SB742457.   
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TABLE 1: 
 
Region 4k (n=14) MA2 (n=17) 
      
Caudate                18.0±11.2 12.14±5.62 
Putamen            17.2±8.82 13.34±6.20 
Frontal 
Cortex   9.28±3.78 7.50±2.17 
Hippocampus               6.69±2.04 5.84±1.61 
Cerebellum           6.12±2.72 5.04±1.45 
 
Regional Estimates of VT (mean±SD) from models with plasma parent input 
functions 
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Table 2 
Brain Region Plasma Input Functions (BPs) Reference Tissue Methods (BPs) Akaike 
  4kdisp MA2 FRTM SRTM FRTM SRTM 
  Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD 
              
Caudate 1.787±0.075 1.349±0.621 1.767±0.805 2.586±1.910 91.166±14.995 90.712±13.272 
Putamen 1.819±0.758 1.587±0.658 1.888±0.954 2.450±1.412 89.154±17.230 88.295±13.055 
Hippocampus 0.074±0.145 0.164±0.072 0.180±0.063 0.184±0.066 79.521±11.391 78.465±11.439 
Frontal Lobe 0.522±0.223 0.489±0.102 0.473±0.090 0.475±0.091 47.517±23.088 46.215±20.646 
Parietal Lobe 0.569±0.357 0.496±0.089 0.478±0.077 0.481±0.077 47.296±23.963 43.441±22.293 
Occipital Lobe 0.383±0.564 0.524±0.084 0.496±0.061 0.500±0.059 51.289±22.605 46.615±20.627 
Temporal Lobe 0.335±0.594 0.484±0.102 0.464±0.089 0.468±0.094 51.756±16.586 50.292±16.778 
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TABLE 3: 
Subject 
Number 
FRTM BP - 
Ketanserin 
% 
Occupancy   
FRTM BP - SB-
742457 
% Occupancy 
Baseline 5 Hours 5 Hours   5 Hours Day 7 5 Hours Day 7 
  Putamen (5-HT6)     Putamen (5-HT6)     
Subject 5 0.865 0.882 0   0.419 ~ 52 ~ 
Subject 6 * 1.196 0.359 70   0.292 ~ 76 ~ 
Subject 7 * 1.466 0.306 79   0.378 ~ 74 ~ 
Subject 8 1.449 1.355 6   0.437 ~ 70 ~ 
Subject 9 1.020 ~ ~   0.407 0.376 60 63 
Subject 10 0.837 ~ ~   0.387 0.430 54 49 
    Mean 3       64 56 
  Caudate (5-HT6)     Caudate (5-HT6)     
Subject 5 0.655 0.594 9   0.226 ~ 65 ~ 
Subject 6 * 0.768 0.190 75   0.160 ~ 79 ~ 
Subject 7 * 0.546 0.075 86   0.098 ~ 82 ~ 
Subject 8 1.839 1.413 23   0.114 ~ 94 ~ 
Subject 9 0.955 ~ ~   0.163 0.198 83 79 
Subject 10 0.713 ~ ~   0.005 0.045 99 94 
    Mean 16       84 87 
  
Frontal cortex (5-
HT2A)     
Frontal cortex (5-
HT2A)     
Subject 5 0.212 0.185 13   0.052 ~ 75 ~ 
Subject 6 * 0.272 Poor fit ~   0.050 ~ 81 ~ 
Subject 7 * 0.390 0.281 28   0.175 ~ 55 ~ 
Subject 8 0.277 0.178 36   0.145 ~ 48 ~ 
Subject 9 0.202 ~ ~   0.059 0.136 71 33 
Subject 10 0.326 ~ ~   0.163 0.249 50 24 
    Mean 25       63 29 
 
*Represents subjects who received SB742457 before ketanserin 
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TABLE 4: 
 
 
 
 
Baseline Day 7 Day 14 Day 21 Day 28 Day 7 Day 14 Day 21 Day 28
Putamen (5-HT6)
Subject 11 1.085 No scan ~ 0.346 ~ No scan ~ 68 ~ 68
Subject 12 0.909 0.324 ~ ~ 0.297 64 ~ ~ 67 66
Subject 13 1.001 ~ 0.283 0.300 ~ ~ 72 70 ~ 71
Subject 14 1.359 ~ 0.300 ~ 0.328 ~ 78 ~ 76 77
70
Subject 15 0.994 0.307 0.397 ~ ~ 69 60 ~ ~ 65
Subject 16 1.042 0.295 0.312 ~ ~ 72 70 ~ ~ 71
68
Subject 17 0.890 0.350 0.411 ~ ~ 61 54 ~ ~ 58
Subject 18 1.052 0.379 0.328 ~ ~ 64 69 ~ ~ 67
62
Caudate (5-HT6)
Subject 11 0.510 No scan ~ 0.037 ~ No scan ~ 93 ~ 93
Subject 12 0.912 0.067 ~ ~ 0.178 93 ~ ~ 81 87
Subject 13 1.092 ~ 0.051 0.173 ~ ~ 95 84 ~ 90
Subject 14 1.044 ~ 0.010 ~ 0.121* ~ 99 ~ 88* 99
92
Subject 15 0.754 Poor fit 0.336 ~ ~ Poor fit 55 ~ ~ 55
Subject 16 0.697 -0.052 0.004 ~ ~ 108 99 ~ ~ 104
79
Subject 17 0.944 0.051 0.009 ~ ~ 95 99 ~ ~ 97
Subject 18 1.746 -0.06118 -0.027 ~ ~ 104 102 ~ ~ 103
100
Frontal cortex (5-HT2A)
Subject 11 0.272 No scan ~ 0.191 ~ No scan ~ 30 ~ 30
Subject 12 0.228 0.087 ~ ~ 0.108 62 ~ ~ 53 58
Subject 13 0.238 ~ 0.048 0.080 ~ ~ 80 67 ~ 74
Subject 14 0.257 ~ 0.096 ~ 0.072 ~ 63 ~ 72 68
57
Subject 15 0.373 0.277 0.196 ~ ~ 26 48 ~ ~ 37
Subject 16 0.273 0.162 0.211 ~ ~ 41 23 ~ ~ 32
35
Subject 17 0.280 0.190 0.213 ~ ~ 32 24 ~ ~ 28
Subject 18 0.269 0.223 0.215 ~ ~ 17 20 19
23
*SRTM value (FRTM value = 0.48808)
FRTM BP % Occupancy Mean 
Occupancy
Subject 
Number
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Figure 2: 
 
 
Baseline PET images showing the biodistribution of [
11
C]GSK215083 in the human brain 
(scale bar=%ID/L). 
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Figure 3: 
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Figure 4: 
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Figure 5: 
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